Therapeutics News and Research

RSS

Quanterix Simoa® Technology Powers Breakthrough Alzheimer’s Disease Research Presented by Eli Lilly and Company at Alzheimer’s Association International Conference (AAIC) 2021

Ultra-sensitive Simoa® HD-X technology powers new findings that detect rapid reduction of plasma P-tau217 from donanemab, Lilly’s investigational antibody therapy for Alzheimer's disease at 12 weeks

From Quanterix 9 Aug 2021

New compound inspired by tapeworm drugs shows two-pronged effectiveness against COVID-19

A group of medications long prescribed to treat tapeworm has inspired a compound that shows two-pronged effectiveness against COVID-19 in laboratory studies, according to a new publication appearing online in the journal ACS Infectious Disease.

9 Aug 2021

Virus-like particles reveal unexpected mechanism for increased fitness and spread of SARS-CoV-2

Researchers in the United States have developed a new model for testing mutations in the four structural proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

9 Aug 2021

Researchers develop a novel process for producing pure RNA

Researchers at the University of Massachusetts Amherst recently unveiled their discovery of a new process for making RNA.

6 Aug 2021

Aducanumab approval for Alzheimer's may provide a proof of concept that can be rapidly improved upon

The recent US Food and Drug Administration (FDA) approval of aducanumab – which has the potential to treat Alzheimer's disease – may provide a proof of concept that can be rapidly improved upon, writes Dennis Selkoe in this Perspective.

6 Aug 2021

Study: Neglecting development of therapeutics may repeat history and replicate vaccine inequality

A new policy report released today by the global non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) highlights how the development of therapeutics has been relatively neglected in the global response to COVID-19 and warns that with the few treatment innovations available principally in high-income countries, we risk repeating history and replicating the vaccine inequality that has become a defining characteristic of this global pandemic.

6 Aug 2021

Expert highlights the progress and challenges in developing blood tests for Alzheimer's disease

Given the progress in therapeutics for Alzheimer's disease (AD), including the recent approval of aducanumab – the first anti-amyloid immunotherapy approved by the FDA for the disease – there is a need for simple blood tests that could be used to ensure accurate diagnosis and assess therapeutic progress.

6 Aug 2021

Multivalent nanobodies show improved neutralization activity against SARS-CoV-2

A state-of-the-art engineering approach toward improving the neutralizing activity of a cross-reactive nanobody, previously generated against the original SARS virus, showed it can be an attractive and viable option against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study is published in the journal Advanced Therapeutics.

5 Aug 2021

New method for producing pseudotyped virus particles bearing spike protein of SARS-CoV-2

A new study discusses the development of an improved protocol based on cell lines that can consistently express S proteins.

5 Aug 2021

Specific and sensitive biomarker in the blood predicts symptomatic COVID-19 infection

Researchers remain perplexed as to why some patients infected with SARS-CoV-2, the virus responsible for COVID-19, remain asymptomatic while other patients develop severe disease symptoms.

5 Aug 2021

Experimental drug combination extends survival in mice with lung cancer, study finds

A combination of experimental drugs increased the attack of immune cells on non-small cell lung cancer (NSCLC) to extend survival in mice, a new study found.

5 Aug 2021

New DNA writing technique can precisely and efficiently edit bacterial genomes

Biological engineers at MIT have devised a new way to efficiently edit bacterial genomes and program memories into bacterial cells by rewriting their DNA.

5 Aug 2021

Investigational treatment improves survival rate of babies lacking thymus

An investigational treatment pioneered by a Duke Health pediatrician resulted in a one-year survival rate of 77% among children born with a rare condition in which they lack an immune system.

4 Aug 2021

Rigaku Acquires Life Science Imaging Equipment Manufacturer MILabs

Rigaku Corporation (Headquarters: Akishima-shi, Tokyo; President: Toshiyuki Ikeda; "Rigaku"), a leading manufacturer of X-ray analysis equipment, has acquired all issued shares of MILabs B.V. (Headquarters: Houten, The Netherlands; CEO and CSO: Dr. Frederik Beekman; “MILabs”)

From Rigaku Corporation 4 Aug 2021

Next-generation CRISPR tools and therapies improved by modified RNA guides

A new type of gene-editing tool, CRISPR-Cas13, has shown promise in RNA targeting. Previous studies have shown the tool as a potential treatment method for viral diseases, including coronavirus disease (COVID-19).

3 Aug 2021

Biolabs LA at The Lundquist Institute reaches highly significant capacity milestone

BioLabs LA at The Lundquist Institute, a co-working and incubator facility for high-potential bioscience start-ups, has reached 100% capacity ahead of schedule.

3 Aug 2021

“Sybodies” protect against SARS-CoV-2 in hamster model

Researchers in China, The Netherlands, France, and Switzerland have identified synthetic nanobodies or “sybodies” that exhibit potent neutralizing activity against severe acute respiratory syndrome coronavirus (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic.

3 Aug 2021

Therapeutics News and Research

Quanterix Simoa® Technology Powers Breakthrough Alzheimer’s Disease Research Presented by Eli Lilly and Company at Alzheimer’s Association International Conference (AAIC) 2021

New compound inspired by tapeworm drugs shows two-pronged effectiveness against COVID-19

Virus-like particles reveal unexpected mechanism for increased fitness and spread of SARS-CoV-2

Researchers develop a novel process for producing pure RNA

Aducanumab approval for Alzheimer's may provide a proof of concept that can be rapidly improved upon

Study: Neglecting development of therapeutics may repeat history and replicate vaccine inequality

Expert highlights the progress and challenges in developing blood tests for Alzheimer's disease

Multivalent nanobodies show improved neutralization activity against SARS-CoV-2

New method for producing pseudotyped virus particles bearing spike protein of SARS-CoV-2

Specific and sensitive biomarker in the blood predicts symptomatic COVID-19 infection

Experimental drug combination extends survival in mice with lung cancer, study finds

New DNA writing technique can precisely and efficiently edit bacterial genomes

Investigational treatment improves survival rate of babies lacking thymus

Rigaku Acquires Life Science Imaging Equipment Manufacturer MILabs

Next-generation CRISPR tools and therapies improved by modified RNA guides

Biolabs LA at The Lundquist Institute reaches highly significant capacity milestone

“Sybodies” protect against SARS-CoV-2 in hamster model

Flagging potential molecular predictors of response to biological therapies in ulcerative colitis

Researchers develop a new way to detect placenta accreta spectrum disorder during pregnancy

Anti-parasitic drug prevents pancreatic cancer's initiation, progression and metastasis in mice

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News